Clinical Trial Update: Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating four doses of rotigotine delivered via a transdermal patch for symptom control in Parkinson's disease. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rotigotine (Neupro) (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-12-10